British Land (BLND.L) - Company Research
Last Updated: 27 April 2026
British Land (LSE: BLND) is the FTSE 100 commercial REIT that has spent the past five years methodically rebalancing the portfolio away from regional shopping centres into London Campuses, Retail Parks and London Urban Logistics. The Q4 trading update on 21 April 2026 raised FY26 EPS guidance from 28.5p to 28.9p and FY27 to at least 30.5p, with portfolio value +2.3% in the period and a record AI-driven office letting (Anthropic 158,000 sq ft at One Triton Square). The Life Science REIT scheme of arrangement completed on 20 April 2026, adding ~£150 m of life-sciences assets and ~1% EPS accretion in FY27. Simon Carter announced his departure in January 2026 with a 12-month notice period; the search for a successor is in flight. This report covers the FY25 financials, the Sep-2025 H1 print, the development pipeline (Norton Folgate, Canada Water, Broadgate Tower) and the principal risks at gilt yields, retail-park yield compression and CEO succession.
1. Company Snapshot
| Company | The British Land Company plc |
| Ticker / ISIN | LSE: BLND / GB0001367019 (ADR: BTLCY; OTC: BRLAF) |
| Sector / Industry | FTSE 100 UK REIT – diversified commercial real estate |
| HQ | York House, 45 Seymour Street, London W1H 7LX |
| CEO | Simon Carter (announced departure 12 Jan 2026; 12-month notice period) |
| CFO | Bhavesh Mistry (ex-Tesco) |
| Founded | 1856 |
| Fiscal year end | 31 March |
| Share price (recent) | ~391.30p (Stockopedia near-real-time); intraday range up to ~404.7p on 21 Apr 2026 trading-update day |
| 52-week range | 318.60p – 432.00p |
| Market cap | ~£4.0 bn (post Life Science REIT share issuance) |
| Shares in issue | ~999.9 m (excl. 11.27 m treasury; 1,011.17 m gross) |
| EPRA NTA per share | 579p (30 Sep 2025); 567p (31 Mar 2025) |
| Portfolio value | £9,801 m (30 Sep 2025); £9,486 m (31 Mar 2025) |
| FY25 dividend | 22.80p (interim 12.24p + final 10.56p) |
| Trailing dividend yield | ~4.78% |
| FY26 EPS guidance (Apr-26) | 28.9p (raised from 28.5p) |
| Next results | FY26 prelims – 20 May 2026 |
2. Bull Case vs Bear Case
| Bull Case | Bear Case |
|---|---|
| Q4 trading update raised FY26 EPS guidance from 28.5p to 28.9p and FY27 to ≥ 30.5p; LfL net rental growth 6% (Campuses +12%) over the period. | ~32% discount to EPRA NTA (579p) on a ~391p share price reflects gilt-yield sensitivity and ongoing skepticism on London office values. |
| Anthropic 158,000 sq ft letting at One Triton Square (Regent’s Place) confirmed in April 2026 trading update – the AI-driven office demand thesis at scale. | Simon Carter departure (announced 12 Jan 2026) with 12-month notice creates leadership transition risk; successor process underway. |
| Defensive debt profile – weighted average debt maturity 5.0 years (Group), 97% hedged for FY26, no material refinancing requirement until mid-2029, £1.7 bn undrawn at H1 FY26. | LTV crept to 39.1% at H1 FY26 (vs 38.1% FY25 / 37.3% FY24); Net debt / EBITDA 8.0× remains elevated relative to history. |
| FY25 portfolio +1.6% with retail parks +7.1%; H1 FY26 portfolio rose to £9.8 bn; ERV growth +4.9% in FY25 (above 3–5% guidance) and +4.9% in latest update. | FY21 IFRS loss of £(1,083)m illustrates the downside in a stress: REIT NTAs are highly sensitive to discount-rate moves and capex retrenchment. |
| Life Science REIT acquisition completed 20 April 2026 (~£150 m, 0.07 BLND shares + 14.1p cash per LSR share); ~1% EPS accretion in FY27; expands into life sciences cluster. | Retail-park yield compression has been the principal driver of recent portfolio uplift; reversal would weigh on NTA and total return. |
3. What Does This Company Actually Do?
British Land is a residential-light, commercial-led UK REIT. The portfolio split at the most recent FY25 disclosure (31 March 2025) is roughly: Campuses ~58% (Broadgate, Regent’s Place, Paddington Central, Canada Water masterplan); Retail Parks ~32% (rebuilt since 2021 from disposals of regional shopping centres); London Urban Logistics ~10% (warehousing conversions including former Homebase sites). Meadowhall – once a corner-stone shopping centre – was fully sold to Norges Bank Investment Management in May 2024 (BLND’s 50% stake for £360 m, valuing the centre at £720 m); BLND retained the asset-management contract.
The Life Science REIT scheme of arrangement completed on 20 April 2026, adding a small life-sciences allocation that becomes a fourth segment label.
Portfolio composition (FY25, 31 March 2025):
| Segment | ~% of portfolio | Notes |
|---|---|---|
| Campuses | ~58% | Broadgate, Regent’s Place, Paddington Central, Canada Water |
| Retail Parks | ~32% | Rebuilt since 2021 via £738 m of acquisitions at 7.1% blended yield |
| London Urban Logistics | ~10% | Conversions inc. former Homebase sites |
Occupancy was 98% across the portfolio at FY25 (Campuses 97%, Retail/LUL 99%) and 95% at H1 FY26 (Campuses 92%, Retail/LUL 98%).
4. The Business Model
British Land collects rent from commercial tenants, recycles capital between segments and develops new space (offices, retail parks, urban logistics, mixed-use). Profit is reported on two bases: an EPRA "underlying" measure that strips out revaluations (the basis on which the dividend policy of 80% of underlying EPS, paid as a Property Income Distribution, is set) and IFRS profit/loss which includes valuation movements.
Capital structure (30 September 2025):
- Group net debt: £2.7 bn (gross £2.8 bn).
- Including JV share: Net debt £3.8 bn (gross £4.0 bn).
- Weighted average debt maturity: 5.0 years (Group); 4.7 years (incl. JV).
- Hedging: 97% hedged for FY26; 77% on average over the next five years.
- Refinancing requirement: No material refinancing until mid-2029.
- Unsecured committed facilities: £2.3 bn.
- Credit rating: Fitch A (stable).
- EPRA cost ratio: 17.5% (FY25, vs 16.4% FY24).
FY25 financing activity: £2.2 bn total – £1.0 bn new unsecured RCFs (4 transactions), a new £300 m 7-year unsecured bond, £150 m secured debenture tender repaid, and £700 m extended on RCFs and term loans. Dividend policy: 80% of underlying EPS, paid as a PID.
5. Financial Health
Five-year financials (year ending 31 March):
| Metric | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Underlying profit (£m) | 201 | 251 | ~264 | 268 | 279 |
| Underlying EPS (p) | 18.8 | 27.4 | 28.3 | 28.5 | 28.5 |
| IFRS PAT (£m) | (1,083) | n/a | n/a | 1 | 338 |
| EPRA NTA per share (p) | 648 | 727 | 588 | 562 | 567 |
| DPS (p) | 15.04 | 21.92 | 22.64 | 22.80 | 22.80 |
| LTV (%) | n/a | 32.9 | 36.0 | 37.3 | 38.1 |
| Portfolio value (£m) | n/a | n/a | n/a | 8,684 | 9,486 |
Recent half-year periods:
| Period | Underlying profit (£m) | Underlying EPS (p) | EPRA NTA (p) | Occupancy | LTV |
|---|---|---|---|---|---|
| FY24 (Mar-24) | 268 | 28.5 | 562 | 97% | 37.3% |
| H1 FY25 (Sep-24) | 143 | 15.3 | n/a | n/a | n/a |
| FY25 (Mar-25) | 279 | 28.5 | 567 | 98% | 38.1% |
| H1 FY26 (Sep-25) | 155 (+8%) | 15.4 | 579 | 95% | 39.1% |
| FY26 trading update | guide 28.9p FY26 EPS | n/a | n/a | 95% | n/a |
FY25 highlights: revenue +1.6% portfolio uplift; like-for-like net rental growth +3% (Campuses +2%, Retail/LUL +5%); ERV growth +4.9% (Campuses 6.5%, Retail Parks 4.4%); 3.3 m sq ft of lettings 8.6% ahead of ERV; disposals £597 m and retail-park acquisitions £738 m at 7.1% blended yield.
6. Valuation & Market Data
| Share price | ~391.30p (recent); 399.50p observed on/around 21 Apr 2026 |
| Market cap | ~£4.0 bn (post Life Science REIT share issuance) |
| Enterprise value (proportional) | ~£7.7 bn (~£4.0 bn equity + ~£3.8 bn proportional net debt) |
| EPRA NTA per share | 579p (Sep-25); higher implied per FY26 trading update +2.3% portfolio uplift |
| P/EPRA NTA | ~32% discount on 391p / 579p |
| Trailing dividend yield | ~4.78% |
| P/E (reported, IFRS basis) | ~12.83× |
| LTV | 39.1% (Sep-25) |
| Weighted avg debt maturity | 5.0 yr (Group); 4.7 yr (incl. JV) |
| EPRA cost ratio | 17.5% (FY25) |
| Net debt / EBITDA | 8.0× |
| 52-week range | 318.60p – 432.00p |
7. What Are They Building / What’s Coming?
The committed development pipeline expanded to 3.3 m sq ft at FY25 (vs 2.4 m sq ft prior). Selected schemes:
| Scheme | Size / status | Notes |
|---|---|---|
| Norton Folgate (Spitalfields/Shoreditch) | 335,000 sq ft office-led; targeted completion 2026 | Reed Smith pre-let 126,800 sq ft; 64% let/under offer at July 2025; net-zero carbon target (~434 kg CO2e/sqm embodied) |
| 1 Broadgate / Broadgate Tower | Modernisation; late-2026 completion | 3-storey extension, 6,200 sq ft terrace |
| Regent’s Place / One Triton Square | Anthropic 158,000 sq ft letting (Apr-26 update) | One Triton Square 78% let, 16% under offer |
| Canada Water masterplan | 53-acre, JV with AustralianSuper | Revised plan approved by Deputy Mayor of London (early 2025); up to 4,184 homes, 2.5 m sq ft workspace, 1 m sq ft retail/leisure, 3.5-acre park; £13 m contribution to step-free Surrey Quays Station, summer 2026 |
| Urban Logistics conversions | ~10% of portfolio | Includes former Homebase sites |
| Life Science REIT (post 20-Apr-26 close) | ~£150 m portfolio | Targeted ~1% EPS accretion in FY27 |
8. Competitive Landscape
British Land sits in a London-led commercial REIT cohort alongside Landsec, with retail parks and logistics peers further afield. Selected comparators:
| Company | Market cap (Apr-26) | Portfolio value | Focus |
|---|---|---|---|
| British Land (BLND) | ~£4.0 bn | £9.8 bn (Sep-25) | Diversified: campuses + retail parks + LUL |
| Landsec (LAND) | n/d | £10.0 bn (Mar-25) | London offices + retail / mixed-use |
| Derwent London (DLN) | n/d | £4.9 bn (Dec-23) | Central London offices |
| Great Portland Estates (GPE) | n/d | n/d | West End offices |
| Shaftesbury Capital (SHC) | ~£2.6 bn | £5.2 bn / 2.7 m sq ft | Covent Garden / Soho / Carnaby |
| Hammerson (HMSO) | ~£1.6 bn (Feb-26) | £3.5 bn (Dec-25, +33%) | Bullring, Brent Cross etc. |
| SEGRO (SGRO) | ~£9.0–9.8 bn | £22.0 bn / 117 m sq ft | UK + 7 European countries logistics |
| LondonMetric (LMP) | ~£4.3–4.7 bn | £7.4 bn | UK logistics-led |
| Tritax Big Box (BBOX) | ~£4.45 bn | £6.82 bn | UK Big Box logistics |
Hard market-share percentages are not the relevant comparison for a REIT cohort – these companies compete for capital and tenants on portfolio quality and scale rather than aggregate market share. Most competitive overlap is between Landsec and BLND in London offices, and between SEGRO/LMP/BBOX/BLND in urban logistics.
9. Leadership and Ownership
| Chief Executive Officer | Simon Carter (announced step-down 12 Jan 2026; 12-month notice; moving to GIC-owned P3 Logistics Parks) |
| Chief Financial Officer | Bhavesh Mistry (ex-Tesco deputy CFO) |
| Tenure of CEO | Joined BLND 2004; CFO 2018; CEO since 2020 |
Top institutional holders (per Yahoo / Investing.com syntheses):
| Holder | ~% of shares |
|---|---|
| BlackRock, Inc. | ~9.7–10% |
| The Vanguard Group | ~5.7% |
| Other top holders (typically Schroder Investment Management, Janus Henderson) | ~5.3–5.4% each |
| Aggregate institutional ownership | ~86–88% |
Norges Bank Investment Management is the buyer of British Land’s 50% Meadowhall stake (May 2024); it is not a confirmed direct equity holder of BLND in available filings – the Meadowhall transaction was at the asset level, not a corporate stake. The new CEO destination (P3 Logistics Parks) is GIC-owned, but GIC is not a confirmed BLND shareholder in available sources.
Recent director dealings: A PDMR Shareholding RNS was filed on 14 April 2026 (Investegate RNS 9515332). Specific transaction details should be reviewed via Investegate before relying on quantitative figures here; this article does not include them due to incomplete public extraction.
10. Risks and Challenges
- London office vacancy – structural-demand questions for offices remain; partly offset by AI/tech leasing wave (Anthropic, etc.). Q1 2026 trading update suggests demand returning to high-quality West End / Midtown campuses.
- Retail-park yield reversal – portfolio uplift in FY25 was driven by retail-park yield compression (+7.1% values vs ~+5% H1); reversal would dent NTA and total return.
- Gilt yield / rate sensitivity – REIT NTAs sensitive to discount-rate movements; LTV crept to 39.1% at H1 FY26.
- Refinancing risk – minimal short-term: no material maturity until mid-2029; £1.7 bn undrawn at H1 FY26.
- Planning / delivery risk on Canada Water – masterplan was revised in 2025 for cost / viability; further redesigns possible.
- IFRS valuation movement risk – FY21 IFRS loss £(1,083)m illustrates the downside in stress.
- Leadership transition risk – Simon Carter departing; CEO succession process underway with 12-month notice.
- Integration risk on Life Science REIT – closed 20 April 2026; small relative to BLND but a new asset class.
11. Recent Developments
Last week:
- 21 Apr 2026 – Q4 trading update: FY26 EPS guidance raised from 28.5p to 28.9p; FY27 raised from 30.2p to ≥30.5p; LfL net rental growth 6% (campuses +12%); 3.8 m sq ft leasing 7.2% ahead of ERV; Anthropic 158,000 sq ft at One Triton Square confirmed; total accounting return 8.1%; portfolio valuation +2.3%; ERV +4.9%.
- 21 Apr 2026 – Admission of 24,500,000 new ordinary shares to LSE (consideration for Life Science REIT scheme of arrangement).
- 20 Apr 2026 – Life Science REIT scheme of arrangement effective; FTSE Russell index changes triggered.
- 14 Apr 2026 – Director PDMR shareholding RNS (Investegate RNS 9515332).
Last six months:
- Jan 2026 – Recommended £150 m cash-and-share offer for Life Science REIT (announced after talks reported).
- 12 Jan 2026 – Simon Carter announces departure to lead GIC-owned P3 Logistics Parks; 12-month notice.
- 18 Nov 2025 – H1 FY26 results: underlying profit £155 m (+8%), EPS 15.4p, NTA 579p, DPS 12.32p, LTV 39.1%, 4% LfL net rental growth; H1 lettings 1.4 m sq ft 5.3% ahead of ERV.
- 14 Jan 2026 – H1 FY26 interim dividend (12.32p) paid (ex-div 4 Dec 2025).
12. Key Dates Coming Up
| Date | Event |
|---|---|
| 20 May 2026 | FY26 preliminary results announcement |
| May / Jun 2026 | Final dividend ex-div / record / payment dates set with FY26 results |
| July 2026 (typical) | 2026 AGM (date to be confirmed via britishland.com) |
| November 2026 (typical) | H1 FY27 interim results |
| Summer 2026 | Surrey Quays Station step-free upgrade completion (Canada Water contribution) |
| 2026 | Targeted completion of Norton Folgate (335,000 sq ft) |
| Late 2026 | Targeted completion of Broadgate Tower modernisation |
Explore further on ChartsView:
Disclaimer: This research note is prepared for educational and informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. ChartsView and its authors are not registered investment advisers. All financial figures are sourced from British Land press releases (Q4 trading update 21 April 2026, FY25 results, H1 FY26 results), Investegate RNS announcements and reputable financial media as of 27 April 2026 and may be subject to revision after the FY26 prelims on 20 May 2026. UK REIT investing carries the additional risks that gilt yields, occupier demand, planning approvals and yield-driven valuation movements can move share prices and net asset values materially in either direction.
Loading research report…
13. Thesis Verdict
The central thesis. British Land is a UK commercial REIT generating rental income from three core segments at FY25: Campuses (~58%, including Broadgate, Regent's Place, Paddington Central and Canada Water), Retail Parks (~32%) and London Urban Logistics (~10%), with a small life-sciences allocation added via the Life Science REIT scheme that completed on 20 April 2026. The structural driver is rental and ERV growth across high-quality London campuses and retail parks, evidenced by FY25 ERV growth of 4.9% and the Q4 FY26 trading update showing 6% like-for-like net rental growth (Campuses +12%). The nearest catalysts are the raised FY26 EPS guidance to 28.9p, FY27 guidance of ≥30.5p, the Anthropic 158,000 sq ft letting at One Triton Square, and ~1% EPS accretion from the Life Science REIT deal in FY27.
What would confirm or break it. Confirmation would come from sustained ERV growth, further campus lettings, and stable LTV around the 39.1% H1 FY26 level. Materialisation of retail-park yield reversal, further gilt-yield-driven discount-rate moves, or a repeat of FY21-style IFRS valuation losses of £(1,083)m would invalidate the thesis. CEO succession execution following Simon Carter's January 2026 departure, Canada Water planning delivery, and Life Science REIT integration are also key disclosure points to watch.
Watchpoints
- ConfirmsSubsequent earnings and filings reinforcing the figures presented in this report.
- ConfirmsSubsequent earnings and filings reinforcing the figures presented in this report.
- InvalidatesAny disclosure that directly contradicts a material claim in the bull case.
Diagnostic grid
Generated by ChartsView research tooling. Thesis strength measures how well the evidence in this report supports the company's stated thesis — it is NOT a buy/sell rating or price target. ChartsView is not authorised by the FCA to provide regulated investment advice. Generated 27 Apr 2026.